Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 6, 2017, at 10:30 a.m. ET in New York, NY. In addition, the Company will participate on the Inflammatory Disease panel at the JMP Securities Life Sciences Conference on June 20, 2017, at 4:00 p.m. ET in New York, NY.

A live webcast of Concert’s presentation at the Jefferies conference may be accessed in the Investor section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About ConcertConcert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005227/en/

Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
[email protected]

Source: Concert Pharmaceuticals, Inc.

You May Also Be Interested In

• 25th U.S. Patent Awarded to Bold Laser Automation for Advanced Laser Technology
• Arcadia Capital Advises InformedDNA on Divestiture of Genetic Testing Utilization Management Business Unit to Zyter
• MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology